Previous 10 | Next 10 |
Ekso Bionics Holdings, Inc. (EKSO) Q4 2020 Earnings Conference Call February 25, 2020 4:30 PM ET Company Participants Matt Steinberg – Investor Relations-Lazar Finn Partners Jack Peurach – President and Chief Executive Officer Bill Shaw – Chief Commercial Officer Jack Gle...
Ekso Bionics Holdings (EKSO): Q4 GAAP EPS of -$0.48 misses by $0.18.Revenue of $2.25M (-39.5% Y/Y) misses by $0.33M.Press Release For further details see: Ekso Bionics Holdings EPS misses by $0.18, misses on revenue
RICHMOND, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and twelve months ended December 31, 2020...
RICHMOND, Calif., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the fourth quarter and full year 2020 after th...
Ekso Bionics shares have doubled in three months, but the fundamental narrative has not changed enough to support the valuation. Leadership has used the opportunity to raise $40 million in new equity, giving the company a large balance sheet buffer. Efforts to return to growth in ...
RICHMOND, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced the closing of its previously announced underwritten public offering of...
Gainers: Applied UV (AUVI) +367%.Comstock Holding Companies (CHCI) +125%.KalVista Pharmaceuticals (KALV) +112%.Veru (VERU) +60%.Heat Biologics (HTBX) +58%.SemiLEDs (LEDS) +45%.U.S. Well Services (USWS) +41%.Tilray (TLRY) +41%.Eastside Distilling (EAST) +40%.FSD Pharma (HUGE) +35%.Lo...
Ekso Bionics' (EKSO) underwriter has agreed to increase the size of the previous offering and purchase ~3.9M common shares at $10.25/share.Expected gross proceeds are ~$40M. Underwriter's over-allotment is an additional ~585.4K shares. Net proceeds will be used for working capital and other g...
RICHMOND, Calif., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics”), an industry leader in exoskeleton technology for medical and industrial use, today announced that, due to demand, the underwriter has agreed to increase the size of...
Ekso Bionics (EKSO) entered into an underwriting agreement with H.C. Wainwright & Co. to purchase on a firm commitment basis 975,610 shares at a price to the public of $10.25 per share, less underwriting discounts and commissions. Underwriter's a 30-day option to purchase up to an ad...
News, Short Squeeze, Breakout and More Instantly...
Ekso Bionics Holdings Inc. Company Name:
EKSO Stock Symbol:
NASDAQ Market:
Ekso Bionics Holdings Inc. Website:
SAN RAFAEL, Calif., July 22, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter 2...
Collaboration Expands Use of EksoNR and Ekso Indego Devices in Rehabilitation and Community Settings to Better Improve Patient Quality of Life SAN RAFAEL, Calif., June 25, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company” or “Ekso...
Brings Strategic Healthcare Expertise and Extensive Experience with the U.S. Department of Veterans Affairs (VA) to Ekso’s Board Deborah Lafer Scher SAN RAFAEL, Calif., June 17, 2024 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”...